OctoPlus tries to get drug-delivery tentacles into generics

OctoPlus, a drug-delivery company based in the Netherlands, is actively looking for partnerships with specialty manufacturers of generic drugs, which OctoPlus believes can benefit from its controlled-release technology. In-PharmaTechnologist reports that OctoPlus sees an extra source of revenue coming from generics that lack the expertise to enter specialty markets.

"Our team has identified a number of high-value opportunities in specialty generics, where we can co-invest and leverage our world-class expertise in formulation development," said Jan Egberts, CEO of OctoPlus, in a news release.

The company's second-quarter results saw increased revenue from drug-delivery technologies, partially offset by a drop in earnings due to support for Locteron, a controlled-release version of interferon. Locteron is undergoing trials to treat hepatitis C. It's based on OctoPlus's PolyActive drug-delivery technology, whose biggest selling points include its biodegradability and low initial release.

PolyActive is one of three drug delivery technologies developed by OctoPlus. The company also boasts of OctoDEX--dextran-based microsphere delivery technology for proteins and particulate systems--and a biodegradable polymeric drug delivery system for the controlled release of peptides and small molecules.

- see the story in In-PharmaTechnologist

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.